'Cardiovascular death' presentation slideshows

Long Term Effects of RV Pacing

Long Term Effects of RV Pacing. Tehran Arrhythmia Center April 2006. To Pace or not to Pace?. Pacing the right ventricle. Deleterious Effects of RV Apical Pacing. Altered left ventricular electrical and mechanical activation Altered ventricular function Less work produced for given LVEDV

1.42k views • 101 slides

Heart Valve selection

Heart Valve selection. Weerachai Nawarawong M.D. Inter-hospital conference March 19, 2011. Mechanical valve advantage. Children Patients <40 yrs High reoperation risk Small annular size Atrial fibrillation Pregnancy desired Patients > 70 yrs High thromboembolism risk

813 views • 64 slides

Pharmocotherapy of Ischaemic Heart Disease

783 views • 63 slides

Matthew R. Weir, M.D. Professor and Director Division of Nephrology

779 views • 62 slides

Matthew R. Weir, M.D. Professor and Director Division of Nephrology

623 views • 62 slides

Hypertension & Cardiovascular Risk Factors

Hypertension & Cardiovascular Risk Factors. Final Year Cardiology Teaching 2003-4. Outline. Global burden of cardiovascular disease Epidemiology of cardiovascular disease Hypertension Epidemiology Clinical features Investigation Cardiovascular risk assessment.

818 views • 56 slides

Should we Monitor Anti-Platelet Treatment?

Should we Monitor Anti-Platelet Treatment?. Rabih R. Azar, MD, MSc, FACC Director of Cardiovascular Research Hotel Dieu de France Hospital Associate Professor of Medicine Saint Joseph University School of Medicine. Should we Monitor Anti-Platelet Treatment?.

858 views • 42 slides

Should we Monitor Anti-Platelet Treatment?

Should we Monitor Anti-Platelet Treatment?. Rabih R. Azar, MD, MSc, FACC Director of Cardiovascular Research Hotel Dieu de France Hospital Associate Professor of Medicine Saint Joseph University School of Medicine. Should we Monitor Anti-Platelet Treatment?.

675 views • 42 slides

Diabetes and CKD- The update

Diabetes and CKD- The update. Dr Ching Chen Hua. Kidneys play a critical role in the management of glucose reabsorption and maintaining the overall metabolic balance in humans.

439 views • 37 slides

Journal Club: Obstructive Sleep Apnea.

465 views • 18 slides

TAILORED CLOPIDOGREL LOADING DOSE ACCORDING TO PLATELET REACTIVITY MONITORING DECREASE EARLY STENT THROMBOSIS

TAILORED CLOPIDOGREL LOADING DOSE ACCORDING TO PLATELET REACTIVITY MONITORING DECREASE EARLY STENT THROMBOSIS . L Bonello , L Camoin-Jau, S Arques, , P . Rossi, C. Boyer, D Panagides, O Wittenberg, P Barragan, F Dignat-George, F Paganelli.

313 views • 17 slides

Enrollment and Outcomes

Enrollment and Outcomes. Duckworth W, et al. N Engl J Med 2009;360:129-139. Characteristics of the Patients at Baseline and Follow-up*. Duckworth W, et al. N Engl J Med 2009;360:129-139. Changes in Median Glycated Hemoglobin Levels from Baseline through 78 Months.

225 views • 12 slides

2017 Annual Report Chart Pack

2017 Annual Report Chart Pack. Increases in Rates of Premature Death, Cardiovascular Death and Drug Deaths. Increases in Mortality Rates, Even Among Some of the Healthiest States. Variation Among States in Changes in Mortality Rates from 2012 to 2017.

125 views • 11 slides

Purpose

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative. Purpose

126 views • 7 slides

168 views • 6 slides

Invasive vs. Selective strategy NSTEMI

Invasive vs. Selective strategy NSTEMI. Objective: To determine whether a routine invasive (RI) strategy reduces the long-term frequency of cardiovascular death or nonfatal MI using a meta analysis of individual data from FRISC II , ICTUS an RITA-3 trials.

169 views • 4 slides

Supplemental Data Figure 1.

Supplemental Data Figure 1. Kaplan-Meier curves of time to Cardiovascular Death, subdivided into quartiles of cystatin C. Number of subjects at risk is presented below figure.

104 views • 1 slides